19 Stocks on a Roll, With More Room to Run
While there's no telling if their short-term momentum will continue, these stocks' long-term prospects look bright.
While there's no telling if their short-term momentum will continue, these stocks' long-term prospects look bright.
The market has been on a roll this year. For the year to date through July 31, the S&P 500 has gained 11.6%.
The top-performing sectors so far this year are technology (gaining more than 18%) and healthcare (up nearly 16%). Over the past three months, though, financials have been strong--up nearly 6% compared with the S&P 500's 4.1% gain. Interestingly, we still see some bargains in these three leading sectors today. Even though the healthcare and financial services sectors are fairly valued in aggregate--each trading at a 1.01 median price/fair value ratio, respectively--and technology is a little overvalued at 1.05, you can unearth some bargains if you do a little digging.
We created a screen using Morningstar Direct software to find some wide- and narrow-moat stocks that have had the wind at their back but still look undervalued. While there's no saying if their positive momentum will continue in the short term, our analysts have confidence that these picks have some room to run over the long haul.
We screened our coverage list for stocks trading at at least a 10% discount to our fair value estimates, with a moat rating of wide or narrow (meaning we think they have competitive advantages that fend off competitors for at least a decade). We added the criterion that the stocks had outperformed the S&P 500 over the trailing three-month period. As of July 31, our screen returned 19 companies.
In healthcare, we see some compelling opportunities in pharmaceutical services firms McKesson (MCK) and AmerisourceBergen Corp (ABC), as well as biotechs Vertex Pharmaceuticals (VRTX) and Biogen (BIIB). In the tech sector five companies look appealing: IT service management company ServiceNow (NOW); Chinese online media company SINA Corp ; Microsoft Corp (MSFT); software-as-a-service company Salesforce.com (CRM); and IT service provider Infosys (INFY). Among financial services companies, asset management firms BlackRock (BLK) and Blackstone Group LP (BX) are each trading at discount to our fair value estimate.
Karen Wallace does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.